Why carry out this study?

Teneligliptin is a dipeptidyl peptidase 4 inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012.

Clinical trials are often limited in terms of their duration, number of patients, and the background characteristics of patients, including renal impairment.

We performed a post-marketing surveillance of teneligliptin to examine the long-term (3 years) safety and efficacy in real-world clinical practice, including in patients with renal impairment and those on dialysis.

What was learned from the study?

Long-term treatment with teneligliptin for up to 3 years had a safety profile consistent with that observed in clinical trials.